18F-Misonidazole PET-CT scan detection of occult bone metastasis

McGowan, Daniel R., Macpherson, Ruth E., Bradley, Kevin M. ORCID: https://orcid.org/0000-0003-1911-3382, Fenwick, John D., Gleeson, Fergus V. and Higgins, Geoff S. 2016. 18F-Misonidazole PET-CT scan detection of occult bone metastasis. Thorax 71 (1) , p. 97. 10.1136/thoraxjnl-2015-207400

Full text not available from this repository.

Abstract

A 67-year-old man with locally advanced non-small cell lung cancer entered a phase I trial combining a novel phosphoinositide 3-kinase inhibitor (BKM120) with palliative radiotherapy.1 The trial uses 18F-misonidazole (FMISO) positron emission tomography (PET)-CT imaging to assess any changes in tumour hypoxia. FMISO is a tracer currently only used in the research setting. A pretreatment FMISO PET-CT scan identified an occult, asymptomatic scapular metastasis (figure 1) undetectable on routine CT imaging (figure 2A). This was subsequently confirmed on MRI imaging. The patient was referred for palliative chemotherapy upon completing the trial. To our knowledge, this is the first published report of FMISO PET-CT detecting an occult metastasis. The FMISO image (figure 1) also shows hypoxia within mediastinal nodes. The enlarged nodes were seen on the routine CT imaging (figure 2B) unlike the occult scapular metastasis.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	BMJ Publishing Group
ISSN:	0040-6376
Date of Acceptance:	14 August 2015
Last Modified:	07 Nov 2022 10:21
URI:	https://orca.cardiff.ac.uk/id/eprint/132008

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item